The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Anti-Cancer MAbS Market At The End Of The 2026–2030 Forecast Period?
The anti-cancer mabs market has experienced significant expansion in recent years. Its valuation is forecast to increase from $71.25 billion in 2025 to $78.12 billion in 2026, progressing at a compound annual growth rate (CAGR) of 9.6%. This historical growth can be attributed to factors such as a rise in global cancer prevalence, the proven clinical effectiveness of monoclonal antibodies, substantial investment in oncology research and development, numerous regulatory approvals for biologics, and enhanced patient survival rates in cancer therapy.
The market for anti-cancer monoclonal antibodies (mAbs) is projected to experience significant expansion in the coming years. It is forecast to achieve a size of $112.41 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.5%. This growth throughout the forecast period can be attributed to several factors, including the advancement of personalized cancer medicine, the increased availability of biosimilar mAbs, a rise in oncology healthcare spending, breakthroughs in antibody engineering, and improved access to biologic therapies. Furthermore, major trends expected during this period include the rising acceptance of targeted immunotherapies, the development and expansion of humanized and bispecific antibodies, a growing reliance on combination cancer therapies, an increased focus on precision oncology, and better manufacturing scalability for mAbs.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9041&type=smp
What Drivers Are Shaping The Future Growth Of The Anti-Cancer MAbS Market?
The global rise in cancer cases is anticipated to boost the anticancer mAbs market. Cancer is defined as a group of diseases marked by uncontrolled cell proliferation, capable of invading and harming healthy body tissues. This growing incidence of cancer is attributed to an aging global population, evolving lifestyles, environmental exposures, and advancements in diagnostic tools leading to higher detection rates. Anticancer monoclonal antibodies (mAbs) are genetically engineered versions of the immune system’s antibodies designed to attach to specific proteins on cancer cells, targeting and destroying them. Consequently, the increasing prevalence of cancer fuels demand for the anticancer mAbs market. For example, in February 2024, accroding to the World Health Organization (WHO), a Switzerland-based United Nations agency, projected new cancer cases to exceed 35 million by 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. Thus, the escalating global prevalence of cancer is a key driver for the growth of the anticancer mAbs market.
What Segment Types Make Up The Anti-Cancer MAbS Market?
The anti-cancer mabs market covered in this report is segmented –
1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types
2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications
3) By End User: Hospitals, Research Institutes, Other End Users
Subsegments:
1) By Murine Antibodies: Murine IgG, Murine IgM, Other Murine Isotypes
2) By Chimeric Antibodies: Chimeric IgG, Chimeric IgM, Other Chimeric Isotypes
3) By Humanized Antibodies: Humanized IgG, Humanized IgM, Other Humanized Isotypes
4) By Other Types: Fully Human Antibodies, Bispecific Antibodies, Conjugated Antibodies, Other Novel Formats
Which Market Trends Are Creating New Opportunities In The Anti-Cancer MAbS Market?
Leading companies in the anti-cancer monoclonal antibodies (mAbs) market are focusing on developing innovative solutions, such as early-phase clinical trials, to advance novel therapeutic candidates and strengthen their competitive position. Clinical trials are defined as structured research studies conducted in human participants to evaluate the safety, dosing, and therapeutic effectiveness of new medical interventions, including targeted antibodies and radioimmunotherapies. For instance, in April 2023, Y-mAbs Therapeutics Inc., a US-based clinical biopharmaceutical company, launched a Phase I clinical trial evaluating GD2-SADA, a pre-targeted radioimmunotherapy designed for GD2-positive solid tumors such as small cell lung cancer, sarcoma, and malignant melanoma. The therapy operates through a two-step mechanism where the SADA protein first selectively binds to GD2-expressing tumor cells, followed by administration of the radioactive ligand 177Lu-DOTA which attaches to the SADA protein to deliver targeted radiation, aiming to maximize tumor cell destruction while minimizing radiation exposure to healthy tissues.
Who Are The Key Players Driving Competition In The Anti-Cancer MAbS Market?
Major companies operating in the anti-cancer mabs market are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, ADC Therapeutics, MacroGenics Inc., Zymeworks Inc.
Read the full anti-cancer mabs market report here:
https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report
Which Geographic Regions Are Influencing Demand In The Anti-Cancer MAbS Market?
North America was the largest region in the anti-cancer MAbS market in 2025. Asia-Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mabs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Anti-Cancer MAbS Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=9041&type=smp
Browse Through More Reports Similar to the Global Anti-Cancer MAbS Market 2026, By The Business Research Company
Anti Cancer Mabs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report
Monoclonal Antibodies Market Report 2026
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report
Monoclonal Antibodies Market Report 2026
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model